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PEMBANGUNAN UJIAN DIAGNOSTIK BERASASKAN DNA BAGI 
PENGESANAN SERENTAK Acinetobacter baumannii, GEN-GEN KERINTANGAN 
ANTIBIOTIK DAN PENGENOTIPAN MELALUI KAEDAH PENJUJUKAN DNA 
 
ABSTRAK 
 
Spesies Acinetobacter telah muncul sebagai patogen penting yang berkait 
dengan penjagaan kesihatan di seluruh dunia. Berdasarkan liputan kajian terhadap 
Acinetobacter, A. baumannii merupakan patogen yang paling ketara implikasinya terhadap 
pelbagai jangkitan kronik dan mengakibatkan kadar morbiditi dan mortaliti yang tinggi 
dalam kalangan pesakit, terutamanya pneumonia yang terkait dengan ventilator dan 
jangkitan saluran darah. Kaedah rutin bagi pengenalpastian patogen pada masa kini tidak 
mampu mengenalpasti Acinetobacter sehingga ke peringkat spesies. Sehubungan itu, kajian 
ini bertujuan untuk membangunkan sebuah assai yang berkebolehan mengesan secara 
serentak genus Acinetobacter, A. baumannii serta empat gen yang mengekod carbapenem-
hydrolyzing class D β-lactamase dan untuk mengkaji epidemiologi molekul bagi pencilan-
pencilan klinikal yang mudah terdedah atau sebaliknya terhadap karbapenem. Bagi mencapai 
objektif kajian, sebuah assai PCR multipleks stabil suhu telah dibangunkan berdasarkan 
primer yang direka secara spesifik pada bahagian gen 16S rRNA, protein membran luaran 
bersaiz 33-36 kDa dan empat gen carbapenem-hydrolyzing class D β-lactamase. Satu 
kawalan dalaman telah dikombinasikan ke dalam assai ini supaya kebolehpercayaan dan 
kekuatan assai ini dapat disahkan. Pengesanan spesifik genus Acinetobacter, A. 
calcoaceticus-A. baumannii kompleks dan A. baumannii pada kultur bakteria tulen dan 
kultur darah spike telah dijalankan dengan menggunakan assai ini. Kajian ini mendapati 
bahawa had terendah pengesanan DNA yang ditulenkan adalah 100 pg, manakala DNA yang 
diperoleh secara penguraian termal sama ada daripada kultur bakteria atau spesimen spike 
dalam darah manusia adalah 106 CFU/ml. Assai ini juga mampu mengesan sekurang-
kurangnya satu CFU sel bakteria daripada medium yang telah diperkaya. Assai ini mampu 
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mengesan Acinetobacter serta gen-gen resistannya dalam masa tiga jam dengan kadar 
spesifisiti dan sensitiviti yang tinggi (100%). Penilaian pecutan kestabilan reagen-reagen 
PCR multipleks stabil suhu menunjukkan bahawa campuran yang divakum-kering ini stabil 
pada suhu bilik selama 232 hari. Assai PCR multipleks stabil suhu ini turut membolehkan 
pengenalpastian bakteria secara serentak dan pengesanan gen resistan yang mungkin berguna 
dalam diagnosis segera bagi mengurangkan kadar morbiditi dan mortaliti pesakit yang 
mengalami jangkitan Acinetobacter. Pengkhususan terhadap pencilan-pencilan 
Acinetobacter yang diperoleh daripada 115 spesimen darah terkumpul selama 24 bulan turut 
dijalankan dengan menggunakan analisis pembatasan gen yang diamplifikasi daripada gen 
ribosomal DNA . A. baumannii (60.87%; 70 pencilan) didapati merupakan spesies 
predominan Acinetobacter, diikuti dengan A. nosocomialis (19.13%; 22 pencilan). Daripada 
sejumlah 115 pencilan Acinetobacter, 46.09% dan 5.22% daripada A. baumannii dan 
Acinetobacter spesies masing-masing adalah resistan karbapenem. Pulsed-field gel 
electrophoresis turut dijalankan untuk menentukan hubungan genetik antara pencilan-
pencilan klinikal yang mudah terdedah dan yang tidak mudah terdedah terhadap karbapenem. 
Kesemua pencilan A. baumannii yang tidak mudah terdedah terhadap karbapenem didapati 
membawa gen β-laktamase secara konsisten, iaitu blaOXA-51-like (100%; semua 70 pencilan) 
dan blaOXA-23-like (34.29%; 24 pencilan). Dua kluster predominan merangkumi hampir 
kesemua pencilan A. baumannii yang tidak mudah terdedah terhadap karbapenem setiap 
tahun. Berdasarkan analisis multiple-locus variable-number tandem-repeat analysis, 
pencilan-pencilan A. baumannii dalam kajian ini kebanyakannya didapati berasal daripada 
klonal antarabangsa warisan II yang tersebar meluas serata dunia. Kajian ini seterusnya 
mendapati bahawa kemunculan ahli yang resistan karbapenem di kalangan genus 
Acinetobacter (selain daripada A. baumannii) menggambarkan kepentingan penggunaan 
agen antimikrobial secara berhemah serta pelaksanaan kaedah-kaedah kawalan jangkitan 
agar perkembangan fenotip dan penyebaran klonal resistan di penempatan hospital dapat 
dikurangkan. 
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DEVELOPMENT OF A DNA-BASED METHOD FOR SIMULTANEOUS 
DETECTION OF Acinetobacter baumannii, ANTIMICROBIAL RESISTANCE 
GENES AND ITS GENOTYPES BY DNA FINGERPRINTING 
 
ABSTRACT 
 
Acinetobacter species have emerged as important healthcare associated 
pathogens worldwide. Of the described Acinetobacter, A. baumannii constitutes as the most 
significant causative agent implicating various severe infections, especially ventilated 
associated pneumonia and bloodstream infections, associated high mortality and morbidity in 
patients. Current routine identification systems are unable to identify Acinetobacter to the 
species level. Hereof, this study aimed to develop a reliable tool for simultaneous detection 
of Acinetobacter genus, A. baumannii and four genes encoding the carbapenem-hydrolyzing 
class D β-lactamases, and to investigate the molecular epidemiology of carbapenem 
susceptible and non-susceptible A. baumannii clinical isolates in a hospital setting. A 
thermostabilized multiplex PCR assay was developed with primers designed on specific 
sequence regions of 16S rRNA gene, 33-36 kDa outer membrane protein and four 
carbapenem-hydrolyzing class D β-lactamase genes to achieve the goal of this study. An 
internal control was incorporated to validate reliability and robustness of the assay. Specific 
detection of Acinetobacter genus, A. calcoaceticus-A. baumannii complex and A. baumannii 
on pure bacterial cultures and spiked blood cultures was demonstrated using the developed 
assay. The assay yielded detection limits of 100 pg of purified DNA and 106 CFU/ml with 
DNA thermolysates prepared from either bacterial cultures or spiked human whole blood 
specimens. The assay was capable to detect at least one CFU of bacterial cells in a pre-
enriched medium. The assay detected Acinetobacter with its resistance genes in three hours 
with high specificity and sensitivity (100%). Accelerated stability evaluation of 
thermostabilized multiplex PCR reagents demonstrated that vacuum-dried mixes were stable 
at room temperature for approximately 232 days. The developed thermostabilized multiplex 
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PCR assay enabled simultaneous bacterial identification and detection of its resistance gene 
which would be useful in rapid diagnosis to reduce morbidity and mortality of patients with 
Acinetobacter infections. Speciation on Acinetobacter isolates recovered from 115 blood 
specimens collected over 24-month period with amplified ribosomal DNA restriction 
analysis was performed. A. baumannii (60.87%; 70 isolates) was found to be the 
predominant Acinetobacter genomic species followed by A. nosocomialis (19.13%; 22 
isolates). Of the total 115 Acinetobacter isolates, 46.09% and 5.22% of A. baumannii and 
Acinetobacter species, respectively, were carbapenems-resistant. Pulsed-field gel 
electrophoresis was performed to ascertain genetic relatedness of carbapenem susceptible 
and non-susceptible A. baumannii clinical isolates. All the carbapenem non-susceptible A. 
baumannii isolates were consistently found to harbour β-lactamase gene, blaOXA-51-like (100%; 
all 70 isolates) and blaOXA-23-like (34.29%; 24 isolates). Two predominant clusters contained of 
mostly carbapenems non-susceptible A. baumannii isolates were observed in each year of 
study. Based on the multiple-locus variable-number tandem-repeat analysis, the 
characterized A. baumannii isolates mostly belonged to the international clonal lineage II, of 
which is worldwide distributed. Finding of this study further demonstrated the emergence of 
carbapenem resistance in members within the Acinetobacter genus (other than A. baumannii), 
emphasizing the importance of wisely prescribed antimicrobial agents and stringent 
implementing infection control measures to reduce further the development of resistance 
phenotypes and clonal spreading in clinical settings.  
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Introductory and microbiology of Acinetobacter genus 
Acinetobacter, derived from a word of Greek, “akinetos”, means non-motile, was proposed 
to distinguish non-motile bacteria from motile microorganisms within genus of 
Achromobacter (Brison and Prévot, 1954). However, the proposed genus designation was 
not widely accepted until year 1968 (Baumann et al., 1968). Taxonomy of Acinetobacter 
genus underwent a great refinement since year 1980s parallel with the emergence of 
Acinetobacter as causative pathogens for healthcare associated infections in global hospital 
settings (Dijkshoorn et al., 2007). 
 
1.1.1 Taxonomy and microbiology of Acinetobacter species 
In current taxonomic classifications, members of Acinetobacter genus are classified under 
family of Moraxellaceae within Gammaproteobacteria, a suborder of Proteobacteria (Peleg et 
al., 2008). The Acinetobacter genus comprises Gram-negative, aerobic, non-fastidious, 
glucose non-fermentative, non-motile bacteria with guanine and cytosine content of 39% to 
47% (Peleg et al., 2008). Most Acinetobacter species are metabolic versatile which can grow 
easily on basic microbiological culture media (Visca et al.  ¸2011). In fact, a culture medium 
contains acetate and nitrate as source of carbon and nitrogen, respectively, is used to enrich 
Acinetobacter growth and recover them from composite microbial communities in 
specimens (Visca et al.  ¸ 2011). Furthermore, clinically relevant Acinetobacter genomic 
species demonstrate an optimal growth at 37°C, however, this growth temperature may not 
applicable to all environmental Acinetobacter species (Visca et al.  ¸2011). 
 
In year 1986, 11 of 12 Acinetobacter isolations from various specimen types were 
unambiguously delineated with formal species names assigned for only a few genomic 
species (Bouvet and Grimont, 1986). Thereafter, valid species names were given to those 
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previously described Acinetobacter genomic species with provisional designations (Krizova 
et al., 2015; Nemec et al., 2011; Nemec et al., 2010; Tjernberg and Ursing, 1989; Nishimura 
et al., 1988; Bouvet and Grimont, 1986). Additional novel Acinetobacter genomic species 
were later isolated from various sources and identified, expanding number of members 
within the genus. Currently, Acinetobacter genus encompasses at least 38 genomic species, 
in which 30 and eight genomic species were assigned with valid species names and 
provisional designations, respectively (Table 1.1). 
 
1.1.2 Natural reservoir of Acinetobacter species 
As an overall, Acinetobacter species are ubiquitous microorganisms in nature, which can be 
easily recovered from various sources following bacterial enrichment cultivations (Peleg et 
al.¸ 2008). Indeed, common isolation of certain Acinetobacter genomic species, particularly 
A. baumannii, A. nosocomialis and A. pittii, from environments, animals and human 
commensals are controversial matters in existing literature (Towner, 2009). Occurrence and 
epidemiology of clinically important Acinetobacter in healthcare institutions have been 
documented. Due to the arguments, the existence of Acinetobacter outside hospitals with 
more focused on A. baumannii has progressively been elucidated in recent studies (Pailhoriès 
et al., 2015a; Rafei et al.  ¸ 2015), providing a better perspective on their potential 
environmental and community reservoirs, albeit precise natural reservoirs are still obscure. 
 
Species distribution of Acinetobacter on inanimate substances has been determined for water, 
soil, vegetable, meat, milk, fish and cheese samples (Rafei et al.  ¸ 2015; Choi et al.  ¸ 2012; 
Houang et al., 2001; Berlau et al., 1999b). An exploratory survey on swabs sampled from a 
range of environments together with soil samples in South Korea, found Acinetobacter 
isolations possessed 7.1% (29 isolates) of all 409 bacterial isolates, in which A. baumannii, A. 
pittii and A. nosocomialis only contained a total of seven isolates (Choi et al.  ¸ 2012). 
Another survey conducted in Hong Kong, A. baumannii represented 23% among 
Acinetobacter isolated from 66 soil samples (Houang et al., 2001). Moreover, A. baumannii  
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Table 1.1 Classification of named and tentative genomic species within Acinetobacter genus 
 
Species Genomic species Type or 
representative strain 
Source of isolation Reference 
Acinetobacter baumannii 2 ATCC 19606 Human specimens and hospital environmental samples Bouvet and Grimont, 1986 
Acinetobacter baylyi  DSM 14961 Activated sludge Carr et al., 2003 
Acinetobacter beijerinckii  NIPH838 Soil, water Visca et al., 2011 
Acinetobacter bereziniae 10 ATCC 17924 Human specimens, hospital environmental samples,  Nemec et al., 2010;  
   sewage Bouvet and Grimont, 1986 
Acinetobacter bouvetii  DSM 14964 Activated sludge Carr et al., 2003 
Acinetobacter brisouii  DSM 18516 Peat layer Anandham et al. 2010 
Acinetobacter calcoaceticus 1 ATCC 23055 Soil Bouvet and Grimont, 1986 
Acinetobacter gerneri  DSM 14967 Activated sludge Carr et al., 2003 
Acinetobacter grimontii  DSM 14968 Activated sludge Carr et al., 2003 
Acinetobacter guillouiae 11 ATCC 11171 Human specimens, sewage, activated sludge, water, soil, Nemec et al., 2010;  
   raw milk, contact lens Bouvet and Grimont, 1986 
Acinetobacter gyllenbergii  NIPH2150 Human specimens Visca et al., 2011 
Acinetobacter haemolyticus 4 ATCC 17906 Human specimens Bouvet and Grimont, 1986 
Acinetobacter Iwoffii 8/9 ATCC 15309 Human and animal specimens Bouvet and Grimont, 1986 
Acinetobacter johnsonii 7 ATCC 17909 Human and animal specimens, waste water Bouvet and Grimont, 1986 
Acinetobacter junii 5 ATCC 17908 Human specimens Bouvet and Grimont, 1986 
Acinetobacter kyonggiensis   KSL5401-037 Sewage treatment plant Lee and Lee, 2010 
Acinetobacter nosocomialis 13TU ATCC 17903 Human specimens Nemec et al., 2011;  
    Tjernberg and Ursing, 1989 
Acinetobacter parvus  NIPH384 Human specimens Nemec et al., 2003 
Acinetobacter pittii 3 ATCC 19004 Human specimens and hospital environmental samples Nemec et al., 2011;  
    Bouvet and Grimont, 1986 
Acinetobacter radioresistens 12 IAM 13186 Cotton and soil Nishimura et al., 1988;  
    Bouvet and Grimont, 1986 
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Table 1.1 continued 
Species Genomic species Type or 
representative strain 
Source of isolation Reference 
Acinetobacter rudis   LMG 26107 Raw milk and waste water Vaz-Moreira et al., 2011 
Acinetobacter schindleri  NIPH1034 Human specimens Nemec et al., 2001 
Acinetobacter septicus  AK001 Human specimens and catheter tip samples Kilic et al., 2008 
Acinetobacter soli  KCTC 22184 Soil Kim et al., 2008 
Acinetobacter tandoii  DSM 14670 Activated sludge Carr et al., 2003 
Acinetobacter tjernbergiae  DSM 14971 Activated sludge Carr et al., 2003 
Acinetobacter towneri  DSM 14962 Activated sludge Carr et al., 2003 
Acinetobacter ursingii  NIPH137 Human specimens Nemec et al., 2001 
Acinetobacter variabilis 15TU NIPH2171 Human and animal specimens Krizova et al., 2015 
Acinetobacter venetianus  ATCC 31012 Marine water Visca et al., 2011 
 6 ATCC 17979 Human specimens Bouvet and Grimont, 1986 
 13BJ or 14TU ATCC 17905 Human specimens Visca et al., 2011 
 14BJ CCUG 14816 Human specimens Visca et al., 2011 
 15BJ SEIP 23.78 Human specimens Visca et al., 2011 
 16 ATCC 17988 Human specimens Visca et al., 2011 
 17 SEIP Ac87.314 Human specimens, soil Visca et al., 2011 
 Between 1 and 3 ATCC 17903 Human specimens Bouvet and Grimont, 1986 
  Close to 13TU 10090 Human specimens Gerner-Smidt and Tjernberg, 1993 
Abbreviations: ‘BJ’: Bouvet and Jeanjean; ‘TU’: Tjernberg and Ursing 
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was also recovered from manure agricultural soil and pig slurry in United Kingdom (Byrne-
Bailey et al., 2009) and agriculture environments (fish and shrimp farms) in Southeast Asia 
(Huys et al., 2007). 
 
On the other hand, Acinetobacter carriage on human superficial body sites was found to be 
more frequent in hospitalized patients (75%) compared to healthy ambulatory volunteers 
(approximately 45%), with both populations were dominated by A. Iwoffii (47% to 61%) 
(Berlau et al., 1999a; Seifert et al., 1997). Moreover, A. johnsonii, Acinetobacter genomic 
species 15BJ, A. radioresistens, A. pittii, A. nosocomialis and A. baumannii were also 
isolated at lower percentages (21% to 0.5%). Controversial findings on the prevalence of 
Acinetobacter species distribution as human skin commensals were reported. Comparing to 
previous surveys, A. pittii (36%), A. nosocomialis (15%), Acinetobacter genomic species 
15TU (6%) and A. baumannii (4%) were more frequently detected on skin of healthy Hong 
Kong residents (Chu et al., 1999). Skin carriage of A. calcoaceticus, A. baumannii, A. pittii 
and A. nosocomialis was not detected on healthy United States soldiers (Griffith et al., 2007). 
Furthermore, incidence of Acinetobacter in human faeces was determined with 224 
specimens collected from non-hospitalized individuals, only 24 faecal specimens yielded 
three Acinetobacter genomic species of A. johnsonii (7.5%), Acinetobacter genomic species 
11 (2.2%) and A. baumannii (0.9%) (Dijkshoorn et al., 2005). Besides that, A. baumannii 
was also recovered from body lice sampled from elementary school children (Bouvresse et 
al., 2011) and homeless people (La Scola and Raoult, 2004).. 
 
Apart from human specimens and abiotic surfaces, A. baumannii is also regarded as an 
emerging opportunistic pathogen in veterinary medicine and its epidemic spread among 
animals in veterinary healthcare settings have been described (Pailhoriès et al., 2015a; 
Endimiani et al., 2011; Zordan et al., 2011; Brachelente et al., 2007). In a study conducted in 
Germany, A. baumannii isolates obtained from several veterinary clinics were resistance to 
multiple antimicrobial agents tested and most of them were genetically congruent with 
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epidemic clonal lineages (Zordan et al., 2011). Among 141 animals sampled from veterinary 
clinics located at La Réunion Island, only 12 isolations yielded A. baumannii (8.5%) which 
exhibited susceptible or multidrug-resistant phenotype with diverse genotypic profiles 
(Pailhoriès et al., 2015a). Outside hospital epidemiology of A. baumannii in Lebanon was 
investigated and yielded 30 A. baumannii of a total 110 Acinetobacter isolations from 
animals (Rafei et al.¸ 2015). All A. baumannii isolates were susceptible to most 
antimicrobial agents tested and exhibited novel genotypic profiles. These findings are 
therefore indicating that animals may constitute as a potential reservoir for A. baumannii 
transmission to environments, animals or humans (Pailhoriès et al., 2015a; Rafei et al.  ¸
2015). However, further systematic studies are needed to gain a better insight on interactions 
between humans and potential reservoirs in causing Acinetobacter infections. 
 
1.2 Clinical manifestation of Acinetobacter species 
Acinetobacter are well recognized as significant nosocomial pathogens implicating various 
infections, such as pneumonia, secondary meningitis, skin and soft tissue infections, wound 
infections, urinary tract infections and bloodstream infections (Dijkshoorn et al., 2007). Most 
of the infections are primarily attributed to A. baumannii and a lesser extent to A. 
nosocomialis and A. pittii (Visca et al.  ¸ 2011; Dijkshoorn et al., 2007). While, other 
Acinetobacter genomic species of A. Iwoffii  ¸ A. ursingii, A. johnsonii, A. parvus, A. 
radioresistens, A. haemolyticus, A. junii, A. beijerinckii, A. bereziniae, A. gyllenbergii, A. 
schindleri, Acinetobacter genomic species 15TU and Acinetobacter genomic species 16 are 
regarded as emerging causative pathogens in human related nosocomial infections with 
majority restricted to bacteraemia, septicaemia and pneumonia, albeit low incidences were 
reported (Wisplinghoff et al., 2012; Turton et al.  ¸2010; Boo et al.¸ 2009). Infections caused 
by non-A. baumannii are often benign clinical courses and least mortality on infected 
patients (Visca et al.  ¸2011). 
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1.2.1 Risk factor of Acinetobacter acquisition and infection 
Several retrospective studies have been conducted to identify risk factors for acquisition and 
infection with Acinetobacter. The identified risk factors included previous antimicrobial 
therapy (Inchai et al., 2015; Huang et al., 2014; Zheng et al.  ¸ 2013; Huang et al., 2012; 
Punpanich et al.  ¸2012), premature birth (Punpanich et al.¸ 2012; Al Jarousha et al., 2009), 
intensive care unit admission (Huang et al., 2014), undergone invasive procedures such as 
mechanical ventilation and total parenteral nutrition (Huang et al., 2014; Zheng et al., 2013; 
Huang et al., 2012; Punpanich et al.¸ 2012), systemic and severe illnesses (Inchai et al., 2015; 
Huang et al., 2014; Zheng et al.¸ 2013; Huang et al., 2012) as well as intubation of 
indwelling devices such as intravenous catheters and arterial line catheters (Huang et al., 
2014; Huang et al., 2012). 
 
1.2.2 Nosocomial infections 
1.2.2.1 Ventilator associated pneumonia 
Ventilator associated pneumonia is a common healthcare associated infection among patients 
admitted to critical care settings with mortality rates in ventilated patients ranged from 20% 
to 70% (Rosenthal et al.¸ 2011). A retrospective Vietnamese study reported substantial 
annual increments in Acinetobacter isolations from tracheal aspirate specimens of ventilated 
patients admitted to an intensive care unit over a 11-year duration (from year 2000 to year 
2010), responsible for 46% of all pneumonia cases in year 2010 (Nhu et al., 2014). 
Surveillance data retrieved from Asian Network revealed the prevalence of Acinetobacter in 
ten Asian countries, with the lowest percentage observed in Hong Kong (9.8%) to the 
highest percentage of 49.8% observed in Thailand (Chung et al., 2011). The prevalence of 
Acinetobacter reported for ventilated associated pneumonia was 21.8% in Malaysia (Chung 
et al., 2011). Recent data from The Surveillance Network database revealed 40.5% (12,915 
respiratory specimens) of all significant 31,889 A. baumannii specimens from patients 
admitted to intensive care units throughout 217 United States hospitals (Zilberberg et al., 
2016). Patients with A. baumannii bacteremic pneumonia presented poor prognosis coupled 
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with high antimicrobials resistances and mortality rates compared to patients infected with A. 
nosocomialis (Lee et al.  ¸2013).  
 
1.2.2.2 Bloodstream infection 
Acinetobacter species ranked 10th among the most common etiologic pathogens responsible 
for nosocomial bloodstream infections in United States, accounted for 1.3% (273 of 20,978 
cases) of monomicrobial cases in 49 hospitals over a 7.5-year period (Wisplinghoff et al., 
2004). Data retrieved from another surveillance network revealed 18.9% (7,431 of 39,320 
cases) of A. baumannii cases were derived from patients with bloodstream infections during 
three different time periods throughout 217 United States hospitals (Zilberberg et al., 2016). 
A prospective nationwide surveillance study, Acinetobacter species ranked 4th among the 
most common pathogens responsible for nosocomial bloodstream infections, accounted for 
306 of 2447 monomicrobial cases (12.5%) in 16 Brazilian hospitals over a 2.8-year study 
period (Marra et al., 2011). Besides that, the prevalence of Acinetobacter species responsible 
for bloodstream infections in South Africa, Malaysia and China was 16.0% (McKay and 
Bamford, 2015), 6.1% (Deris et al., 2009) and 4.6% (Wu et al., 2015a), respectively   
 
Of Acinetobacter genomic species causing nosocomial bloodstream infections, A. baumannii 
accounted the most prevalent causative agent, followed by A. nosocomialis, A. pittii and 
other Acinetobacter genomic species (Wisplinghoff et al., 2012; Chuang et al., 2011). These 
pathogens are usually acquired by vulnerable patients undergoing treatment in intensive care 
units (Zilberberg et al., 2016; Wisplinghoff et al., 2012). Less favourable clinical outcomes 
have been observed in patients with A. baumannii infections who also suffered a 
considerable higher mortality than patients infected with other Acinetobacter genomic 
species (Wisplinghoff et al., 2012). In fact, the attributable mortality of A. baumannii 
bacteraemia has been reported as high as approximately 59% in hospitalized population (Liu 
et al.¸ 2014; Chuang et al., 2011). 
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1.2.2.3 Wound infection and traumatic battlefield 
Acinetobacter baumannii is an ordinary microorganism recovered from burn wounds (Cen et 
al.¸ 2015; Keen III et al.¸ 2010) and traumatic wounds of repatriated casualties from Iraq 
(Operation Iraqi Freedom) and Afghanistan (Operation Enduring Freedom) combats 
(Sheppard et al., 2010). Besides that, hospital acquired A. baumannii wound infections have 
also been reported in survivors from natural disasters (earthquake and tsunami), who 
underwent treatment in overloaded healthcare facilities where failures in implementation of 
standard hygiene measures were noted in these settings (Wang et al., 2010; Ukay et al., 
2008). Of casualties suffered traumatic wounds infections, A. baumannii was likely acquired 
during their immediate care at field hospitals with environmental contamination or as a 
consequence of cross transmission between hospitalized soldiers and medical personnel in 
military hospitals (Scott et al.¸ 2007). Furthermore, this pathogen tended to develop greater 
resistance to a wide variety of antimicrobials during prolonged hospitalization and hence, 
leaving clinicians in a difficult situation to prescribe appropriate empirical antimicrobial 
therapy (Visca et al.¸ 2011; Keen III et al.¸ 2010).  
 
1.2.2.4 Urinary tract infection 
Nosocomial urinary tract infection is occasionally caused by Acinetobacter species 
(Djordjevic et al.¸ 2013; Visca et al.¸ 2011). It is often benign in association with urinary 
catheters and occurs in rehabilitation centres more frequently than critical care settings 
(Dijkshoorn et al., 2007). Patients with male gender, previous antimicrobial therapy and 
transferation from other wards have been identified as risk factors relevant to Acinetobacter 
urinary tract infections (Djordjevic et al.  ¸2013).  
 
1.2.3 Community acquired infections 
Acinetobacter species occasionally cause community acquired infections such as urinary 
tract infection, soft tissue infection, wound infection, ocular infection, endocarditis, 
pneumonia and meningitis (Visca et al.¸ 2011; Falagas et al.¸ 2007b). A review article 
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concluded that most of the community acquired infections occurred in tropical or subtropical 
regions, in particular Asia and Australia (Falagas et al.¸ 2007b). Patients with community 
acquired Acinetobacter infections were typically had underlying conditions, such as chronic 
obstructive pulmonary disease, diabetes mellitus, renal disease, alcoholism and heavy 
smoking (Visca et al.¸ 2011; Falagas et al.  ¸2007b). 
 
1.2.4 Clinical impact of Acinetobacter infections 
Clinical outcomes in patients with Acinetobacter infections have been assessed in numerous 
studies (Liu et al., 2015; Chiang et al., 2014; Liu et al.¸ 2014; Kuo et al.  ¸2013; Lee et al., 
2013b; Huang et al., 2012a; Perez et al.  ¸2010). A poorer prognosis was observed in patients 
infected with carbapenem-resistant A. baumannii compared to other Acinetobacter genomic 
species (Liu et al., 2015; Liu et al.¸ 2014; Lee et al., 2013b; Huang et al., 2012a). 
Furthermore, higher mortality rates were reported in hospitalized population with 
carbapenem-resistant A. baumannii bacteraemia or pneumonia (Liu et al., 2015; Lee et al., 
2013b; Huang et al., 2012a). However, true causes in attributing to mortality of patients with 
A. baumannii infections are difficult to assess as this pathogen mostly affects critically ill 
and immunosuppressed population (Visca et al.  ¸ 2011). In a review article, the attributable 
mortality rate of patients with A. baumannii infections was ranged from 8% to 32%, however, 
a conclusive rate could not be formulated due to the heterogeneity in study designs among 
the articles reviewed (Falagas and Rafailidis, 2007a).  
 
1.3 Treatment of Acinetobacter infections 
Antimicrobials susceptibility pattern of Acinetobacter guides clinicians to prescribe 
empirical therapy, however, multidrug-resistant isolates are increasingly encountered in 
clinical practices (Viale et al., 2015; Peleg et al.  ¸2008). Current recommended therapeutic 
options differed between different susceptibility phenotypes of Acinetobacter. 
Aminoglycosides, third generation cephalosporins and a combination of β-lactam and β-
lactamase inhibitors are prescribed for susceptible isolates, carbapenems, amikacin and 
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colistin are used for resistant isolates, while, colistin and tigecycline are used for treating 
multidrug-resistant isolates (Hatcher et al., 2012).  
 
1.3.1 Therapeutic options 
1.3.1.1 Sulbactam 
Sulbactam is a β-lactamase inhibitor with intrinsic bactericidal activity against Acinetobacter 
through its binding to penicillin-binding protein 2 (Michalopoulos and Falagas, 2010). This 
agent is commercially available in a combined formulation with ampicillin or cefoperazone. 
Clinical investigation on effectiveness of sulbactam-containing compound to treat mild to 
severe A. baumannii infections has been documented (Fishbain and Peleg, 2010). Majority of 
the previous studies reported that patients treated with a single sulbactam or ampicillin-
sulbactam were cured or clinically improved, regardless of bacterial susceptibility profiles to 
carbapenems, aminoglycosides and polymyxin (Oliveira et al., 2008; Lee et al., 2007; Ko et 
al., 2004). Moreover, a relatively lower pharmaceutical cost on sulbactam than imipenem 
was reported with sulbactam used to treat susceptible A. baumannii infections (Jellison et al., 
2001). Therefore, sulbactam-containing regimens were recommended as effective 
therapeutics to limit excessive use of carbapenems in clinical practices (Fishbain and Peleg, 
2010; Michalopoulos and Falagas, 2010). 
 
1.3.1.2 Polymyxins 
Polymyxins (polymyxin E or colistin and polymyxin B) are polycationic lipopolypeptides 
that act on bacterial outer membrane resulting in the loss of membrane integrity (Neonakis et 
al.¸ 2011). In recent years, polymyxins have been administered in intensive care settings to 
treat multidrug-resistant A. baumannii infections (Neonakis et al.¸ 2011). Favourable or 
curative outcome has been documented on polymyxin therapy for hospital acquired 
infections caused by multidrug-resistant A. baumannii (Falagas et al., 2010; Gounden et al., 
2009). However, the clinical outcome of patients with colistin administration is always a 
great concern, as treatment may implicate adverse effect of nephrotoxicity, neurotoxicity and 
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neuromuscular blockade (Michalopoulos and Falagas, 2010). Data from several studies 
revealed that accumulative doses of colistin methanesulfonate would increase the risk of 
nephrotoxicity in patients (Neonakis et al.  ¸ 2011; Hartzell et al., 2009). Therefore, a lower 
dosage of polymyxin, with different antimicrobial formulations and careful monitoring on 
patients’ renal function are required to reduce side effects (Michalopoulos and Falagas, 
2010).  
 
1.3.1.3 Tigecycline 
Tigecycline, a 9-t-butylglycylamido semi-synthetic glycycline, represents a modified 
minocycline (Peleg et al.  ¸ 2008) that inhibits bacterial protein synthesis by binding to 30S 
ribosomal subunit (Fishbain and Peleg, 2010). Owing to lack of therapeutic options, 
tigecycline is primarily reserved for multidrug-resistant Gram-negative infections (Neonakis 
et al.¸ 2011). This antimicrobial agent has only been approved for treating intra-abdominal 
and skin infections by Food and Drug Administration (Michalopoulos and Falagas, 2010). 
Even though tigecycline demonstrates good in vitro bactericidal activity against multidrug-
resistant A. baumannii, but its effectiveness in clinical use remains controversial (Gordon et 
al., 2009; Anthony et al., 2008; Gallagher and Rouse¸ 2008; Vasiley et al., 2008). In addition, 
bacterial isolates can develop resistance to tigecycline during the treatment course (Viale et 
al., 2015), thereby, tigecycline therapy is always recommended to be combined with other 
active antimicrobial agents (Michalopoulos and Falagas, 2010).  
 
1.3.2 Antimicrobial combination therapy 
Antimicrobial combination therapy is an alternative to improve bactericidal activity and 
prevent further development or emergence of resistance in Acinetobacter (Peleg et al., 2008). 
Numerous in vitro assessments have been performed on multidrug-resistant A. baumannii 
against various antimicrobial combination regimens, including carbapenems, polymyxins, 
rifampicin, amikacin, tigecycline and cefeperazone-sulbactam (Kiratisin et al., 2010; 
Principe et al.  ¸ 2009; Tripodi et al., 2007; Timurkaynak et al., 2006). Carbapenems are 
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always prescribed together with polymyxin, aminoglycoside or cefeperazone-sulbactam to 
exhibit a synergistic bactericidal effect (Kiratisin et al., 2010; Principe et al.¸ 2009; 
Timurkaynak et al., 2006). Besides that, other synergism combination regimens, carbapenem, 
tigecycline and sulbactam combine with colistin, rifampin or an aminoglycoside have also 
been demonstrated (Michalopoulos and Falagas, 2010).  
 
Despite antimicrobial combination regimens demonstrated in vitro synergistic effects, 
evidences on their clinical effectiveness and safety are still scarce (Durante-Mangoni and 
Zarrilli, 2011). Better clinical outcomes were observed in patients treated with a combination 
regimen of colistin and carbapenem compared to patients treated with other regimens 
(Shields et al.¸ 2012; Falagas et al., 2010). In a recent comparative study, 250 patients with 
bloodstream infections caused by extreme-drug-resistant A. baumannii were treated with 
different antimicrobial regimens (Batirel et al., 2014). In this study, colistin monotherapy (36 
patients) was compared with several antimicrobial combination regimens, such as colistin 
and meropenem (102 patients), colistin and sulbactam (69 patients), and colistin combined 
with other antimicrobials (43 patients) (Batirel et al., 2014). Analyzed data showed that 
patients who received combination regimens demonstrated better outcomes in the 14 days 
survival, eradication rate and mortality than patients who were treated with colistin alone 
(Batirel et al., 2014). 
 
1.3.3 Future therapeutic alternatives 
Bactericidal effects can also be achieved through non-antibiotic therapeutic approaches, such 
as phage therapy, iron chelation therapy, antimicrobial peptides, prophylactic vaccination 
and passive immunization, photodynamic therapy and nitric oxide-based therapy (García-
Quintanilla et al., 2013). All aforementioned approaches have been reviewed with 
limitations and problems needed to overcome for each approach were addressed (García-
Quintanilla et al., 2013). Among the non-antibiotic approaches, antimicrobial peptides are 
regarded as potential antibacterial candidates. In general, peptides comprise of 10 to 48 
14 
 
amino acid residues with non-conserved domains that possess biological activity (Conlon et 
al., 2009). Most peptides share a cationic character and contain ≥ 50% hydrophobic amino 
acids, allowing peptides to interact with microbial cell membranes (Conlon et al., 2009; 
Pazgier et al., 2006).  
 
Several antimicrobial peptides have been demonstrated as having promising synergistic 
effects on multidrug-resistant A. baumannii. Human β-defensin 2, 3 and 4 (Routsias et al., 
2010; Supp et al., 2009; Maisetta et al.¸ 2006) as well as alyteserin-1c (Conlon et al., 2010; 
Conlon et al., 2009) have been reported as potent peptide candidates with rapid bactericidal 
actions against multidrug-resistant A. baumannii. Good bactericidal effects have been 
demonstrated with melittin and mastoparan tested against colistin susceptible and resistant A. 
baumannii clinical isolates (Vila-Farres et al., 2012). Importantly, no bacterial regrowth was 
observed in mastoparan tested against colistin susceptible and resistant isolates, contrary 
findings were observed when those isolates tested with colistin. Therefore, mastoparan has 
been proposed as an alternative therapy for colistin-resistant Acinetobacter infections (Vila-
Farres et al., 2012).  
 
1.4 Mechanism of antimicrobial resistance in Acinetobacter species 
Members of Acinetobacter genus are increasingly resistance to numerous antibacterial agents 
via intrinsic and acquired resistance mechanisms (Espinal et al.  ¸ 2011b). Of all described 
Acinetobacter genomic species, A. baumannii possesses an outstanding ability to rapidly 
accumulate and express various genetic determinants conferring resistance against a broad 
spectrum of antimicrobials, which are usually prescribed for empirical therapy (Poirel et al.¸ 
2011). The foremost mechanisms contributed to antimicrobial resistance, including 
acquisition of resistance determinants through horizontal genes transfer, modification of 
endogenous genes and up regulation of efflux systems (Roca et al.¸ 2012).  
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Wide dissemination of resistance genes among inter- and intra- genetic relatedness bacterial 
species is facilitated by mobile elements, such as integrative and conjugative elements, 
plasmids, transposons, insertion sequence elements, gene cassettes and integrons (Stokes and 
Gillings, 2011). Genomic analysis on distribution of mobile elements, in particular integrons 
and insertion sequence elements, revealed abundance of these elements in different 
Acinetobacter genomic species at various percentages (Touchon et al., 2014). Mobile 
elements play important roles in horizontal acquiring foreign genetic determinants via 
conjugation, transduction or transformation process and then, integrating the acquired 
determinants into bacterial genome (Stokes and Gillings, 2011), thereby, contributing to high 
genetic plasticity leading to genomic diversification among species within Acinetobacter 
genus (Touchon et al., 2014).  
 
1.4.1 Genetic basis of resistance to aminoglycosides, quinolones and polymyxins 
Resistance to aminoglycosides is achieved through modification of hydroxyl or amino group 
by aminoglycoside-modifying enzymes (AMEs). Three AMEs are responsible for 
aminoglycosides resistance, including aminoglycoside acetyltransferases, aminoglycoside 
nucleotidyltransferases and aminoglycoside phosphotransferases (Cho et al., 2009; Nemec et 
al.¸ 2004b). These enzymes are usually associated with class 1 integron and resistance 
islands (Poirel et al., 2011), therefore, they can horizontally transfer and disseminate among 
A. baumannii isolates (Nemec et al.¸ 2004b). The 16S rRNA methylation, mediated by armA 
gene, is another mechanism contributes to the high level of resistance against all formulated 
aminoglycosides (Cho et al., 2009). Genetic analysis on armA gene structure revealed that 
the gene is flanked by an insertion sequence ISCR1, embedded within a transposon Tn1528 
(Tada et al., 2015). Moreover, the presence of armA gene is often co-detected with a blaOXA-
23 or blaNDM-1 gene (Tada et al., 2015; Adams-Haduch et al., 2008).  
 
Resistance to quinolones and fluoroquinolones is due to modification of gyrase or 
topoisomerase IV through point mutation in gyrA and parC gene located within quinolone-
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resistance-determining-region (Lopes et al., 2013; Karah et al., 2011; Zhao et al., 2011), 
resulting in a low affinity for antimicrobials to bind to the enzyme-DNA complex (Poirel et 
al., 2011). The common gyrA and parC mutations, Ser83 to Leu83 substitution in GyrA and 
Ser80 to Leu80 substitution in ParC, have been identified in quinolones- and 
fluoroquinolones-resistant isolates (Jiang et al.  ¸2014; Lopes et al., 2013; Karah et al., 2011; 
Lin et al.¸ 2010b; Hujer et al.  ¸ 2006). Moreover, amino acid substitutions are often 
associated with ciprofloxacin resistance in Acinetobacter clinical isolates (Lin et al.  ¸2010b; 
Adams-Haduch et al., 2008; Hujer et al.¸ 2006). 
 
Resistance to polymyxins is mediated by loss of bacterial lipopolysaccharide (Moffatt et al., 
2011) and PmrAB mutations (Adam et al., 2009). The PmrAB is a two-component signal 
transduction system that encoded by pmrA and pmrB genes, governing expression of pmrC 
gene encodes a phosphoethanolamine transferase enzyme (Poirel et al.¸ 2011). Mutations in 
pmrA and pmrB genes cause overexpression of pmrC gene with addition 
phosphoethanolamine moieties to lipid A, resulting in a decrease of negative charge at 
bacterial outer membrane and eventually impair the affinity of lipopolysaccharide against 
polymyxins (Beceiro et al., 2011). Further, mutations in IpxA and IpxC genes could 
implicate lipid A biosynthesis cause a complete loss of lipopolysaccharide production and a 
high level of colistin resistance in A. baumannii (Moffatt et al., 2011).  
 
1.4.2 Genetic basis of resistance to beta-lactams 
Resistance to β-lactams is typically ascribed to enzymatic and non-enzymatic mechanisms. 
Enzymatic mechanisms involve the production of β-lactam hydrolyzing enzymes, also 
known as β-lactamases, capable to hydrolyze and inactivate β-lactamic antimicrobials. The 
β-lactamases are chromosomal or plasmid encoded by bla gene. While, non-enzymatic 
mechanisms are referred to resistance modes without the production of enzymes to degrade 
and inactivate antibacterial agents.  
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1.4.2.1 Non-enzymatic mechanisms for resistance to beta-lactams  
1.4.2.1.1 Alteration of outer membrane proteins 
The outer membrane of Gram-negative bacteria contains proteins that mediate 
transmembrane passage of amino acids, ions and small molecules needed for cell growth and 
function. Hence, alteration of the membrane permeability can implicate in uptake of amino 
acids and other molecules into the bacterial cells. Correlation between A. baumannii 
proteomic profile and carbapenem susceptibility has been established, reduced in certain 
protein expression may diminish carbapenem diffusion across bacterial outer membrane and 
thereby, decreased susceptibility to carbapenem (Dupont et al., 2005).  
 
A heat-modifiable protein, 29 kDa outer membrane protein, also recognized as CarO protein, 
which was absence from imipenem-resistant A. baumannii with no carbapenemase activity 
was detected in the isolates under studied (Dupont et al., 2005; Limansky et al., 2002). 
Apparent loss of CarO protein in carbapenem-resistant A. baumannii was resulted from carO 
gene disruption by distinct insertion elements (Mussi et al., 2005). Further studies were 
conducted to decipher structural characteristic and function of CarO protein in A. baumannii 
(Zahn et al., 2015; Catel-Ferreira et al., 2011; Siroy et al., 2005; Limansky et al., 2002). 
Findings revealed the alteration in CarO protein expression could implicate ornithine uptake 
(Siroy et al., 2005) and reduce susceptibility to imipenem but not meropenem (Catel-Ferreira 
et al., 2011).  
 
Analysis of outer membrane protein profiles among carbapenems-resistant A. baumannii 
isolates revealed a reduced expression on 43 kDa protein, also known as OprD homologue, 
with 49% homology to Pseudomonas aeruginosa OprD (Dupont et al., 2005). Findings from 
a study suggested that OprD homologue may not be involved in carbapenem resistance 
(Catel-Ferreira et al., 2012). Rather, the regulation of OprD homologue can assist bacterium 
to adapt and survive in magnesium and iron depleted environments (Catel-Ferreira et al., 
2012). Besides, another outer membrane protein, namely 33-36 kDa protein, was also absent 
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from bacterial outer membrane or showed decreased expression in association with 
carbapenem resistance in A. baumannii (del Mar Tomás et al., 2005; Clark, 1996).  
 
1.4.2.1.2 Alteration of penicillin binding proteins 
Role of penicillin binding proteins (PBPs) in resistance mechanism is rarely investigated. As 
an overall, PBPs only confer marginal levels of carbapenem resistance but association with 
the production of β-lactamases, overexpression of efflux pumps or alteration of expression 
level or structure in outer membrane proteins could contribute a higher level of phenotypic 
carbapenems resistance (Yun et al., 2011).  
 
1.4.2.2 Enzymatic mechanisms 
Ambler classification scheme has been applied to classify β-lactamases according to their 
molecular structures into four molecular classes, represented by Ambler class A extended-
spectrum β-lactamases, Ambler class B metallo-β-lactamases, Ambler class C 
cephalosporinases and Ambler class D oxacillinases (Queenan and Bush, 2007). 
 
1.4.2.2.1 Ambler class A extended-spectrum beta-lactamases 
Ambler class A extended-spectrum β-lactamases is always regarded to have minor effects on 
bacterial resistance phenotypes (Roca et al., 2012; Peleg et al., 2008). Extended-spectrum β-
lactamases (ESBLs) of KPC-, CARB-, TEM-, SHV-, CTX-M-, GES-, SCO-, PER- and 
VEB-type have thus far detected in Acinetobacter, compromising efficacy of penicillins, 
cephalosporins and oxyimino-β-lactams, but their hydrolysis capacities can be inhibited by 
clavulanic acid (Roca et al., 2012; Espinal et al., 2011b). Among the described ESBLs, PER- 
and VEB-type, β-lactamases are more frequently detected in Acinetobacter (Roca et al., 
2012; Espinal et al., 2011b; Kolayli et al., 2005) and nosocomial outbreaks caused by 
isolates harbouring both enzymes have been reported (Jeong et al.  ¸2005; Poirel et al., 2003). 
Genetic context analysis revealed an insertion sequence IS26 which is often preceded blaVEB-
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1 gene, forming part of class 1 integron (Poirel et al., 2003). Genes encoding PER-type 
variants (blaPER-1, blaPER-2 and blaPER-7) are associated with insertion sequence elements, 
ISPa12, ISPa13 and ISCR1, as promoter sequence leading to genes expression (Bonnin et al., 
2011b; Pasterán et al., 2006; Poirel et al., 2005a). The blaPER-1 gene is flanked by upstream 
ISPa12 and downstream ISPa13 forming a composite transposon Tn1213 (Poirel et al., 
2005a), blaPER-2 gene is only flanked by a single copy of ISPa12 (Pasterán et al., 2006) while 
ISCR1 present at upstream immediate from blaPER-7 gene (Bonnin et al., 2011). Comparing to 
blaPER-1, expression of blaPER-7 gene could result in a greater resistance to cephalosporins and 
monobactams (Poirel et al., 2011).  
 
1.4.2.2.2 Ambler class B metallo-beta-lactamases 
Ambler class B metallo-β-lactamases is capable of hydrolyzing all β-lactams except 
monobactam aztreonam (Tang et al.  ¸ 2014). Metallo-β-lactamases (MBLs) are zinc-
dependent metalloproteins, which can be inhibited by ethylenediaminetetraacetic acid but do 
not physically interact with β-lactams and β-lactamase inhibitors, such as tazobactam, 
sulbactam and clavulanic acid (Bush and Jacoby, 2010). Metallo-β-lactamases have been 
grouped into six families with most designations derived from the sites of their first positive 
isolations, including active on imipenem (IMP), Verona integron-encoded metallo-β-
lactamase (VIM), Seoul imipenemase (SIM), Sao Paulo metallo-β-lactamase (SPM), 
German imipenemase (GIM) and New Delhi metallo-β-lactamase (NDM) (Yong et al., 2009; 
Queenan and Bush, 2007).  
 
Allelic variants belonging to IMP, VIM, SIM and NDM families have thus far been 
described in Acinetobacter (Tang et al.¸ 2014). Despite MBLs are less frequently detected in 
Acinetobacter than Ambler class D oxacillinases, these enzymes demonstrate 100 to 1000 
folds of hydrolytic activities toward carbapenems (Poirel and Nordmann, 2006a). 
Furthermore, bla gene encoded MBLs are usually located in class 1 integron that contains an 
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array of resistance gene cassettes (Yamamota et al.¸ 2013; Poirel and Nordmann, 2006a). 
Insertion of genes encoding MBLs onto resistance gene cassettes located in integrons are 
embedded within transferable plasmids, act as important vehicles to disseminate resistance 
determinants among Acinetobacter species and across different genera (Poirel and 
Nordmann, 2006a). The IMP enzyme was first described in Pseudomonas aeruginosa 
isolated in Japan (Watanabe et al., 1991). Thereafter, IMP-type enzymes have widely 
disseminated among Gram-negative bacteria including Acinetobacter. The 37 IMP-type 
variants that have been identified with common detection in Acinetobacter included IMP-1, 
IMP-2, IMP-4, IMP-5, IMP-6, IMP-8, IMP-11 and IMP-19 (Zarrilli et al., 2013; Espinal et 
al., 2011b).  
 
Verona integron-encoded metallo-β-lactamases exhibit less than 40% amino acid homology 
to IMP-type enzymes, but share similar substrates profile with a higher affinity towards 
carbapenems (Docquier et al., 2003). The first VIM-type variant, VIM-1, was detected in 
Pseudomonas aeruginosa isolated from Verona, Italy (Lauretti et al., 1999). Five VIM-type 
variants, VIM-1, VIM-2, VIM-3, VIM-4 and VIM-11, have sporadically been detected in 
Acinetobacter isolations from China (Zhao et al., 2015), Egypt (Fouad et al.¸ 2013), India 
(Chaudhary and Payasi, 2013; Amudhan et al., 2012), Saudi Arabia (Al-Sultan et al., 2015) 
and Taiwan (Ku et al., 2015; Lin et al., 2010a). For SIM family, SIM-1 enzyme was initially 
described in A. baumannii derived from a tertiary hospital in Seoul, Korea (Lee et al., 2005). 
This β-lactamase exhibits 64% to 69% amino acid homology to IMP-type variants and 
hydrolyzes penicillins, narrow-spectrum cephalosporins, extended-spectrum cephalosporins 
and carbapenems (Lee et al., 2005). 
 
An allelic variant belonging to NDM family, NDM-1 enzyme, was initially detected in 
Klebsiella pneumoniae and Escherichia coli isolates recovered from a Swedish who returned 
from India (Yong et al., 2009). As similar to other MBLs, NDM-type enzymes confer 
resistance to all β-lactams except aztreonam (Roca et al.  ¸2012). Genes encoding NDM-type 
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variants can be located in bacterial chromosome or plasmids with approximate sizes ranged 
from 30 kb to 50 kb (Chen et al., 2011; Espinal et al., 2011a). Genetic context surrounding 
blaNDM-type showed to be different from other MBLs, often in association with insertion 
sequence ISAba125 and ISAba11 on a transposon Tn125 (Yang et al., 2012; Espinal et al., 
2011a). In most NDM-type positive isolates, blaNDM gene is flanked by two copies of 
insertion sequence ISAba125, alongside ble (bleomycin resistance) and trpF (N-(5’-
phosphoribosyl) anthranilate isomerase) genes at downstream immediate from that gene 
(Espinal et al., 2011a).  
 
1.4.2.2.3 Ambler class C cephalosporinases 
Ambler class C cephalosporinases, also known as AmpC-type β-lactamases, encompasses 
non-inducible chromosomal enzymes are now recognized as Acinetobacter-derived 
cephalosporinases (ADCs) (Tang et al.  ¸ 2014; Hujer et al., 2005). Fifty six ADC-type 
variants have been identified in Acinetobacter, with more than half of those allelic variants 
are found in A. baumannii (Zhao and Hu, 2012; Hujer et al., 2005). The ADC-type enzymes 
confer resistance to all penicillins, extended-spectrum cephalosporins and a combination of 
β-lactam and β-lactamase inhibitor (Drawz et al., 2010). These enzymes constitute basal 
expression levels that possess no effects on β-lactams (Héritier et al., 2006). Nonetheless, 
blaADC-type gene could be overexpressed with acquisition of an upstream insertion sequence 
ISAba1 or ISAba125, resulting in bacterial resistance against extended-spectrum 
cephalosporins but does not compromise efficacy of cefepime and carbapenems (Rezaee et 
al., 2013; Héritier et al., 2006).  
 
1.4.2.2.4 Ambler class D oxacillinases 
Ambler class D oxacillinases involves carbapenem-hydrolyzing activity (hydrolyzes 
imipenem and meropenem but not extended-spectrum cephalosporins and aztreonam), hence, 
β-lactamases belonging to this class are also termed as carbapenem-hydrolyzing class D β-
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lactamases (Poirel and Nordmann, 2006a). Five phylogenetic subgroups of carbapenem-
hydrolyzing class D β-lactamases (CHDLs) have been identified, represented by OXA-51, 
OXA-23, OXA-24, OXA-58 and OXA-143 (Roca et al.¸ 2012). Each subgroup comprises 
allelic variants with different amino acid substitutions in respective sequences. All variants 
are chromosomal or plasmid encoded by bla gene (blaOXA-51/23/24/58/143-like gene), which are 
often associated with mobile elements, such as insertion sequence elements and transposons. 
 
Naturally occurring oxacillinases, represented by OXA-51 subgroup, intrinsic enzymes in A. 
baumannii allowing weak hydrolysis of β-lactamic substrates, mainly to penicillins 
(benzylpenicillin, ampicillin, ticarcillin and piperacillin) and carbapenems (imipenem and 
meropenem) but do not active against expanded-spectrum cephalosporins (Durante-Mangoni 
and Zarrilli, 2011; Poirel and Nordmann, 2006a). More than 68 variants belonging to OXA-
51 subgroup have currently been described in A. baumannii isolations from diverse 
geographical regions (Zhao and Hu, 2012). Presence of an upstream insertion sequence 
ISAba1 or ISAba9 at blaOXA-51-like gene often acts as a strong transcriptional promoter to 
enhance gene expression (Figueiredo et al., 2009; Turton et al., 2006a). 
 
OXA-23 subgroup constitutes OXA-23, OXA-27, OXA-49 and OXA-73 variants (Roca et 
al.¸ 2012; Afzal-Shah et al., 2001). It shares 56% amino acid identity with OXA-51 
subgroup (Poirel and Nordmann, 2006a). The OXA-23 enzyme was first detected in an A. 
baumannii clinical strain isolated from Scotland in year 1985, initially named as ARI-1 
(Paton et al., 1993). Presence of blaOXA-23-like gene in bacterial chromosome or plasmid seems 
to be exclusive in Acinetobacter genus, with an exception when that gene was detected in 
Proteus mirabilis isolated from France (Bonnet et al., 2002). Interestingly, A. radioresistens 
has been identified as the progenitor for blaOXA-23 gene, whose chromosomal encoded blaOXA-
23 gene mobilized into A. baumannii through a transposition event (Poirel et al., 2008). An 
insertion sequence ISAba1 or ISAba4 preceding blaOXA-23-like gene could increase gene 
expression level (Wang et al., 2014; Manageiro et al., 2012). Two genetic structures of 
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blaOXA-23-like gene are identified in multidrug-resistant A. baumannii, one copy of upstream 
insertion sequence ISAba1 preceding blaOXA-23-like gene and blaOXA-23-like gene is flanked by 
two copies of ISAba1 in opposite orientations, both structures are embedded on transposon 
Tn2006, Tn2007 or Tn2008 (Wang et al., 2014; Manageiro et al., 2012; Wang et al., 2011).  
 
OXA-24 subgroup comprises of OXA-24, OXA-25, OXA-26 and OXA-72 variants (Wang 
et al., 2007; Afzal-Shah et al., 2001). Of this subgroup, chromosomal encoded blaOXA-24 gene 
was first described in carbapenem-resistant A. baumannii derived from Spain (Bou et al., 
2000). Oxacillinases classified under this subgroup share 63% and 60% amino acid 
homology with OXA-51 and OXA-23 subgroup, respectively (Poirel and Nordmann, 2006a). 
Genes encoding allelic variants within OXA-24 subgroup can be located in bacterial 
chromosome or plasmid (Roca et al., 2012) in association with XerC/XerD-like recombinant 
sites, a different genetic context mapped for blaOXA-23-like and blaOXA-58-like genes (Merino et 
al.¸ 2010).  
 
OXA-58 subgroup comprises of OXA-58, OXA-96 and OXA-97 variants. It shares 59% 
amino acid identity with OXA-51 subgroup and less than 50% amino acid identity with both 
OXA-23 and OXA-24 subgroups (Poirel and Nordmann, 2006a). The OXA-58 enzyme was 
first detected in a carbapenem-resistant A. baumannii isolated from Toulouse, France (Poirel 
et al., 2005b). The blaOXA-58-like gene is usually plasmid-borne and associated with insertion 
sequence elements of ISAba1, ISAba2 or ISAba3 (Villalón et al., 2015; Migliavacca et al., 
2013; Lee et al., 2012). Similar to genetic structure surrounding blaOXA-23-like gene, blaOXA-58-
like gene is also flanked by two copies of insertion sequence elements, with insertion 
sequence ISAba3 is usually detected at 3’ end, forming a composite transposon (Giannouli et 
al., 2009; Poirel and Nordmann, 2006b).  
 
In OXA-143 subgroup, OXA-143 and OXA-231, are plasmid encoded β-lactamases sharing 
88%, 63% and 52% amino acid identity with OXA-24, OXA-23 and OXA-58 subgroup, 
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respectively (Higgins et al., 2009). The OXA-143 enzyme was first detected in a 
carbapenem-resistant A. baumannii isolated from Brazil in year 2004 (Higgins et al., 2009). 
In contrast to other CHDLs, blaOXA-143 gene appears being associated with neither insertion 
sequence element nor integron, but it is flanked by two copies of replicase genes (Higgins et 
al., 2009).  
 
1.5 Epidemiology of Acinetobacter baumannii harboured carbapenem-
hydrolyzing class D beta-lactamases genes of blaOXA-23/24/58/143-like 
Three distinct A. baumannii clonal lineages, European clone (EU) I, II and III, that were 
responsible for outbreaks in European hospitals have successfully been delineated (Nemec et 
al., 2004a; van Dessel et al., 2004). Sequence-based typing schemes were subsequently 
developed to characterize A. baumannii epidemic clones, represented by group or clonal 
complex 1, 2 and 3 corresponding to EU I, II and III (Wisplinghoff et al., 2008; Turton et 
al.¸ 2007; Bartual et al., 2005). Epidemic EU clones have been reported to be disseminated 
in healthcare institutions worldwide and are now recognized as international clone (ICL) I, II 
and III (Antunes et al., 2014; Visca et al., 2011). Additional five distinct clonal lineages, 
named as worldwide clonal lineage 4, 5, 6, 7 and 8, have been reported as global epidemic 
spread (Higgins et al.¸ 2010a). Indeed, at least nine major clonal complexes including the 
three international clonal lineages have been showed to be distributed worldwide, as revealed 
in a population structure analysis (Zarrilli et al., 2013).  
 
Hospital outbreaks are mostly caused by carbapenem-resistant A. baumannii strains 
harboured bla gene encoding Ambler class D oxacillinases (Kulah et al., 2010; Kohlenberg 
et al., 2009; Ozen et al., 2009). The blaOXA-23-like gene is frequently detected in carbapenem-
resistant isolates and currently, this corresponding gene has been disseminated worldwide 
and spread to different genomic species within the Acinetobacter genus (Roca et al., 2012). 
Epidemic A. baumannii strains harbouring blaOXA-23-like gene are generally assigned to ICL I 
and ICL II clones (Peymani et al., 2012; He et al., 2011; Irfan et al., 2011; Runnegar et al., 
